MD-ESAB-CORPORATION
15.8.2024 12:31:32 CEST | Business Wire | Press release
To enable the industry to track gas process parameters, analyze gas consumption and identify gas leaks and over-consumption, InduSuiteTM, ESAB’s platform of software applications for welding, cutting and robotics, has introduced FloCloud, a gas monitoring software solution. FloCloud combines GCE’s® trusted brand of gas control products with InduSuite’s proven WeldCloud software application platform to build a gas manifold with Mesh WiFi enabled pressure and flow sensors that communicate data to the FloCloud online application.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815098966/en/
FloCloud’s dashboard provides complete gas consumption usage from manifold to torch to track analyze and report any over- or under-consumption events. (Graphic: Business Wire)
FloCloud features an easy-to-use analytics dashboard and reporting system that tracks every end user point and sends notifications if gas pressure drops or if gas flow is outside of WPS (Weld Procedure Specification) parameters, improving real-time data and reducing the need for manual checks.
Additionally, FloCloud tracks complete gas consumption per welding job, per welding operator and per overall project. This information is valuable for cost analysis and job estimating by easily allocating gas cost to a specific job/project to be more competitive in quotes and more profitable in projects. Knowing exactly how much gas is used within the gas supply system also helps regulate preventative maintenance to replace seals and other consumables.
“Fabricators and manufacturers struggle with high gas consumption and have limited knowledge on how much gas is wasted in leaks and overuse,” says Jon Hofmann, Director of Product Management Digital Solutions, InduSuite, an ESAB brand. “Additionally, our customers asked for a tool that provides cost analysis on gas consumption so that they can bid jobs accurately. FloCloud can solve these issues and provide an immediate ROI.”
InduSuite customers with early access to FloCloud have seen the following advantages:
- Stopping leaks and over-consumption saved a large gas consumer in the petrochemical industry more than €1 million on its gas spend and more than 240,000 l (8,475 cu. ft.) in welding gas use.
- Another customer was losing €6,000 per day by shutting the line down to swap gas cylinders. With FloCloud’s tracking mechanism and knowing exactly how much gas is needed per job, the user now never runs out of gas in the middle of a shift and cylinder swaps are completed during scheduled breaks or shift changes.
FloCloud is built to withstand rigorous environments for mid- to high-volume gas users, which include gas distribution companies, welding in oil, gas and petrochemical operations, shipyard and off-shore applications, manufacturers of transportation, construction, mining and agricultural equipment with future offerings coming for specialty gases in food and beverage, hospital and laboratory applications.
To learn more about this new gas monitoring solution, visit FloCloud (indusuite.com).
About ESAB Corporation
Founded in 1904, ESAB Corporation is a focused premier industrial compounder. The Company’s rich history of innovative products, workflow solutions and its business system ESAB Business Excellence (EBX), enables the Company’s purpose of Shaping the world we imagine.TM ESAB Corporation is based in North Bethesda, Maryland and employs approximately 9,000 associates and serves customers in approximately 150 countries. To learn more, visit www.ESABcorporation.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240815098966/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom